The potential of proton beam radiation therapy in intracranial and ocular tumours

Acta Oncologica

Volumn 44, Issue 8, 2005, Pages 862-870

  Blomquist, Erik ^a   Bjelkengren, Göran ^b   Glimelius, Bengt ^a,c  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ARTERIOVENOUS MALFORMATION; BEAM THERAPY; CANCER PATIENT; EYE TUMOR; GLIOMA; HUMAN; HYPOPHYSIS ADENOMA; INTRACRANIAL TUMOR; MEDICAL SPECIALIST; MENINGIOMA; PRIORITY JOURNAL; PROTON RADIATION; REVIEW; SKULL BASE TUMOR;

ADENOMA; BRAIN NEOPLASMS; CHORDOMA; EYE NEOPLASMS; GLIOMA; HUMANS; MENINGEAL NEOPLASMS; PITUITARY NEOPLASMS; PROTONS; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; SKULL NEOPLASMS; SWEDEN;

EID: 28844478883     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/02841860500355934     Document Type: Review

References (93)

1. Andersen AP. Postoperative irradiation of glioblastomas. Results in a randomized series. Acta Radiol Oncol Radiat Phys Biol 1978;17:475-84.
2. Berg G, Blomquist E, Cavallin-Ståhl E. A systematic overview of radiation therapy effects in brain tumours. Acta Oncol 2003;42:582-8.
3. Curran WJ, Jr, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 1993;85:704-10.
4. Kristiansen K, Hagen S, Kollevold T, Torvik A, Holme I, Nesbakken R, et al. Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47: 649-52.
5. Sandberg-Wollheim M, Malmstrom P, Stromblad LG, Anderson H, Borgstrom S, Brun A, et al. A randomized study of chemotherapy with procarbazine, vincristine, and lomustine with and without radiation therapy for astrocytoma grades 3 and/or 4. Cancer 1991;68:22-9.
6. Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys 1979;5:1725-31.
7. Hess CF, Schaaf JC, Kortmann RD, Schabet M, Bamberg M. Malignant glioma: patterns of failure following individually tailored limited volume irradiation. Radiother Oncol 1994;30:146-9.
8. Liang BC, Weil M. Locoregional approaches to therapy with gliomas as the paradigm. Curr Opin Oncol 1998;10:201-6.
9. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.
10. Bigner DD, Brown MT, Friedman AH, Coleman RE, Akabani G, Friedman HS, et al. Iodine-131-labeled anti-tenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results. J Clin Oncol 1998;16:2202-12.
11. Gutin PH, Leibel SA, Wara WM, Choucair A, Levin VA, Philips TL, et al. Recurrent malignant gliomas: survival following interstitial brachytherapy with high-activity iodine-125 sources. J Neurosurg 1987;67:864-73.
12. Riva P, Franceschi G, Arista A, Frattarelli M, Riva N, Cremonini AM, et al. Local application of radiolabeled monoclonal antibodies in the treatment of high grade malignant gliomas: a six-year clinical experience. Cancer 1997;80:2733-42.
13. Scharfen CO, Sneed PK, Wara WM, Larson DA, Phillips TL, Prados MD, et al. High activity iodine-125 interstitial implant for gliomas. Int J Radiat Oncol Biol Phys 1992;24:583-91.
14. Papagikos MA, Shaw EG, Stieber VW. Lessons learned from randomised clinical trials in adult low grade glioma. Lancet Oncol 2005;6:240-4.
15. Blomquist E, Carlsson J. Strategy for planned radiotherapy of malignant gliomas: postoperative treatment with combinations of high dose proton irradiation and tumor seeking radionuclides. Int J Radiat Oncol Biol Phys 1992;22:259-63.
16. Fitzek MM, Thornton AF, Rabinov JD, Lev MH, Pardo FS, Munzenrider JE, et al. Accelerated fractionated proton/photon irradiation to 90 cobalt gray equivalent for glioblastoma multiforme: results of a phase II prospective trial. J Neurosurg 1999;91:251-60.
17. Castro JR, Phillips TL, Prados M, Gutin P, Larson DA, Petti PL, et al. Neon heavy charged particle radiotherapy of glioblastoma of the brain. Int J Radiat Oncol Biol Phys 1997;38:257-61.
18. Castro JR, Saunders WM, Austin-Seymour MM, Woodruff KH, Gauger G, Chen GT, et al. A phase I-II trial of heavy charged particle irradiation of malignant glioma of the brain: a Northern California Oncology Group Study. Int J Radiat Oncol Biol Phys 1985;11:1795-800.
19. Morris GM, Micca PL, Rezvani M, Hopewell JW, Coderre JA. Boron neutron capture therapy: effects of split dose and overall treatment time. J Neurooncol 2001;52:101-10.
20. Carlsson J, Forsell-Aronsson E, Mattsson S, Glimelius B. and the Swedish Cancer Society Investigation Group. Radiation therapy through activation of stable nuclides. Acta Oncol 2002;41:629-34.
21. Tatsuzaki H, Gregoire V, Linggood R. Comparative treatment planning: proton vs x-ray beams against glioblastoma multiforme. Int J Radiat Oncol Biol Phys 1992;22:265-74.
22. Archambeau JO, Slater JD, Slater JM, Tangeman R. Role for proton-beam irradiation in treatment of peciatric CNS malignancies. Int J Radiat Oncol Biol Phys 1992;22:287-94.
23. Möller TR, Brorsson B, Ceberg J, Frodin JE, Lindholm C, Nylen U, et al. A prospective survey of radiotherapy practice 2001 in Sweden. Acta Oncol 2003;42:387-410.
24. Fulham MJ, Bizzi A, Dietz MJ, Shih HH, Raman R, Sobering GS, et al. Mapping of brain tumor metabolites with proton MR spectroscopic imaging: clinical relevance. Radiology 1992;185:675-86.
25. Forssell-Aronsson E, Kjellén E, Mattsson S, Hellström M. and the Swedish Cancer Society Investigation Group. Medical imaging for improved tumour characterisation, delineation and treatment verification. Acta Oncol 2002;41:604-14.
26. Tovi M, Lilja A, Bergstrom M, Ericsson A, Bergstrom K, Hartman M. Delineation of gliomas with magnetic resonance imaging using Gd-DTPA in comparison with computed tomography and positron emission tomography. Acta Radiol 1990;31:417-29.
27. Negendank W. Studies of human tumors by MRS: a review. NMR Biomed 1992;5:303-24.
28. Huncharek M. Meta-analytic re-evaluation of misonidazole in the treatment of high grade astrocytoma. Anticancer Res 1998;18:1935-9.
29. Cancer Incidence in Sweden. Epidemiologiskt Centrum 2003; www.sos.se.
30. Becks JWF. The recurrence of supratentorial meningiomas after surgery. Acta Neurochir 1988;95:3-5.
31. Jaaskelainen J. Seemingly complete removal of histologically benign intracranial meningioma: late recurrence rate and factors predicting recurrence in 657 patients. A multivariate analysis. Surg Neurol 1986;26:461-9.
32. Mirimanoff RO, Dosoretz DE, Linggood RM, Ojemann RG, Martuza RL. Meningioma: analysis of recurrence and progression following neurosurgical resection. J Neurosurg 1985;62:18-24.
33. Bakay RA. Stereotactic radiosurgery in the treatment of brain tumors. Clin Neurosurg 1992;39:292-313.
34. Duma CM, Lunsford LD, Kondziolka D, Harsh GRt, Flickinger JC. Stereotactic radiosurgery of cavernous sinus meningiomas as an addition or alternative to microsurgery. Neurosurgery 1993;32:699-704; discussion 704-5.
35. Ganz JC, Backlund EO, Thorsen FA. The results of Gamma Knife surgery of meningiomas, related to size of tumor and dose. Stereotact Funct Neurosurg 1993;61(Suppl 1):23-9.
36. Goldsmith BJ, Wara WM, Wilson CB, Larson DA. Postoperative irradiation for subtotally resected meningiomas. A retrospective analysis of 140 patients treated from 1967 to 1990. J Neurosurg 1967;80:195-201.
37. Helenowski TK, Pothiawala B. Role of the Gamma Knife in the treatment of large lesions. Stereotact Funct Neurosurg 1993;61(Suppl 1):103-15.
38. Kondziolka D, Lunsford LD, Coffey RJ, Flickinger JC. Stereotactic radiosurgery of meningiomas. J Neurosurg 1991;74:552-9.
39. Lunsford LD. Contemporary management of meningiomas: radiation therapy as an adjuvant and radiosurgery as an alternative to surgical removal? J Neurosurg 1994;80:187-90.
40. Morita A, Coffey RJ, Foote RL, Schiff D, Gorman D. Risk of injury to cranial nerves after gamma knife radiosurgery for skull base meningiomas: experience in 88 patients. J Neurosurg 1999;90:42-9.
41. Gudjonsson O, Blomquist E, Nyberg G, Pellettieri L, Montelius A, Grusell E, et al. Stereotactic irradiation of skull base meningiomas with high energy protons. Acta Neurochir (Wien) 1999;141:933-40.
42. Gudjonsson O, Blomquist E, Lilja A, Ericson H, Bergstrom M, Nyberg G. Evaluation of the effect of high-energy proton irradiation treatment on meningiomas by means of 11C-L-methionine PET. Eur J Nucl Med 2000;27:1793-9.
43. Weber DC, Lomax AJ, Rutz HP, Stadelmann O, Egger E, Timmermann B, et al. Spot-scanning proton radiation therapy for recurrent, residual or untreated intracranial meningiomas. Radiother Oncol 2004;71:251-8.
44. Bolsi A, Fogliata A, Cozzi L. Radiotherapy of small intracranial tumours with different advanced techniques using photon and proton beams: a treatment planning study. Radiother Oncol 2003;68:1-14.
45. Mirimanoff RO. New radiotherapy technologies for meningiomas: 3D conformal radiotherapy? Radiosurgery? Stereotactic radiotherapy? Intensity-modulated radiotherapy? Proton beam radiotherapy? Spot scanning proton radiation therapy. or nothing at all? Radiother Oncol 2004;71:247-9.
46. Crawford PM, West CR, Chadwick DW, Shaw MD. Arteriovenous malformations of the brain: natural history in unoperated patients. J Neurol Neurosurg Psychiatry 1986;49:1-10.
47. Spetzler RF, Hargraves RW, McCormick PW, Zabramski JM, Flom RA, Zimmerman RS. Relationship of perfusion pressure and size to risk of hemorrhage from arteriovenous malformations. J Neurosurg 1992;76:918-23.
48. Pellettieri L, Carlsson CA, Grevsten S, et al. Surgical versus concervative treatment of intracranial arterivenous malformations. A study in surgical decision-making. In: Actra Neurochirurgica. Wien, New York: Springer-Verlag; 1980.
49. Ogilvy CS. Radiation therapy for arteriovenous malformations: a review. Neurosurgery 1990;26:725-35.
50. Wolkov HB, Bagshaw M. Conventional radiation therapy in the management of arteriovenous malformations of the central nervous system. Int J Radiat Oncol Biol Phys 1988;15:1461-4.
51. Guo WY, Wikholm G, Karlsson B, Lindquist C, Svendsen P, Ericson K. Combined embolization and gamma knife radiosurgery for cerebral arteriovenous malformations. Acta Radiol 1993;34:600-6.
52. Karlsson B, Lindquist C, Steiner L. Prediction of obliteration after gamma knife surgery for cerebral arteriovenous malformations. Neurosurgery 1997;40:425-30; discussion 430-1.
53. Colombo F, Benedetti A, Pozza F, Marchetti C, Chierego G. Linear accelerator radiosurgery of cerebral arteriovenous malformations. Neurosurgery 1989;24:833-40.
54. Levy RP, Schulte RW, Slater JD, Miller DW, Slater JM. Stereotactic radiosurgery - the role of charged particles. Acta Oncol 1999;38:165-9.
55. Steinberg GK, Fabrikant JI, Marks MP, Levy RP, Frankel KA, Phillips MH, et al. Stereotactic heavy-charged-particle Bragg-peak radiation for intracranial arteriovenous malformations. N Engl J Med 1990;323:96-101.
56. Silander H, Pellettieri L, Enblad P, Montelius A, Grusell E, Vallhagen-Dahlgren C, et al. Fractionated, stereotactic proton beam treatment of cerebral arteriovenous malformations. Acta Neurol Scand 2004;109:85-90.
57. Vernimmen FJ, Slabbert JP, Wilson JA, Fredericks S, Melvill R. Stereotactic proton beam therapy for intracranial arteriovenous malformations. Int J Radiat Oncol Biol Phys 2005;62:44-52.
58. Miralbell R, Urie M. Potential improvement of three dimension treatment planning and proton beams in fractionated radiotherapy of large cerebral arteriovenous malformations. Int J Radiat Oncol Biol Phys 1993;25:353-8.
59. Wigg DR. A radiobiological basis for the treatment of arteriovenous malformations. Acta Oncol 1999;38(Suppl 14):3-29.
60. Wigg DR. Is there a role for fractionated radiotherapy in the treatment of arteriovenous malformations? Acta Oncol 1999;38:979-86.
61. al Mefty O, Berby L. Skull base chordomas: a management challenge. J Neurosurg 1997;86:287-95.
62. Kondziolka D, Lunsford LD, Flickinger JC. The role of radiosurgery in the management of chordoma and chondrosarcoma of the cranial base. Neurosurgery 1991;29:38-45; discussion 45-6.
63. Hug EB, Sweeney RA, Nurre PM, Holloway KC, Slater JD, Munzenrider JE. Proton radiotherapy in management of pediatric base of skull tumors. Int J Radiat Oncol Biol Phys 2002;52:1017-24.
64. Munzenrider JE, Liebsch N. Proton therapy for tumors of the skull base. Strahlenther Onkol 1999;175(Suppl):257-63.
65. Suit HD, Goitein M, Munzenrider J, Verhey L, Davis KR, Koehler A, et al. Definitive radiation therapy for chordoma and chondrosarcoma of base of skull and cervical spine. J Neurosurg 1982;56:377-85.
66. Igaki H, Tokuuye K, Okumura T, Sugahara S, Kagei K, Hata M, et al. Clinical results of proton beam therapy for skull base chordoma. Int J Radiat Oncol Biol Phys 2004;60:1120-6.
67. Hug EB, Loredo LN, Slater JD, DeVries A, Grove RI, Schaefer RA, et al. Proton radiation therapy for chordomas and chondrosarcomas of the skull base. J Neurosurg 1999;91:432-9.
68. Terahara A, Niemierko A, Goitein M, Finkelstein D, Hug E, Liebsch N, et al. Analysis of the relationship between tumor dose inhomogeneity and local control in patients with skull base chordoma. Int J Radiat Oncol Biol Phys 1999;45:351-8.
69. Rosenberg AE, Nielsen GP, Keel SB, Renard LG, Fitzek MM, Munzenrider JE, et al. Chondrosarcoma of the base of the skull: a clinicopathologic study of 200 cases with emphasis on its distinction from chordoma. Am J Surg Pathol 1999;23:1370-8.
70. Hug EB, Slater JD. Proton radiation therapy for chordomas and chondrosarcomas of the skull base. Neurosurg Clin N Am 2000;11:627-38.
71. Noel G, Habrand JL, Mammar H, Pontvert D, Haie-Meder C, Hasboun D, et al. Combination of photon and proton radiation therapy for chordomas and chondrosarcomas of the skull base: the Centre de Protontherapie D'Orsay experience. Int J Radiat Oncol Biol Phys 2001;51:392-8.
72. Colli B, Al-Mefty O. Chordomas of the craniocervical junction: follow-up review and prognostic factors. J Neurosurg 2001;95:933-43.
73. Austin-Seymour M, Munzenrider J, Linggood R, Goitein M, Verhey L, Urie M, et al. Fractionated proton radiation therapy of cranial and intracranial tumors. Am J Clin Oncol 1990;13:327-30.
74. Feuvret L, Noël G, Calugaru V, Terrier P, Habrand J. Chondromyxoid fibroma of the skull base: differential diagnosis and radiotherapy. Two case reports and a review of the literature. Acta Oncol 2005;in press.
75. Austin JP, Urie MM, Cardenosa G, Munzenrider JE. Probable causes of recurrence in patients with chordoma and chondrosarcoma of the base of skull and cervical spine. Int J Radiat Oncol Biol Phys 1993;25:439-44.
76. Debus J, Haberer T, Schulz-Ertner D, Jakel O, Wenz F, Enghardt W, et al. Carbon ion irradiation of skull base tumors at GSI. First clinical results and future perspectives]. Strahlenther Onkol 2000;176:211-6.
77. Schulz-Ertner D, Haberer T, Jakel O, Thilmann C, Kramer M, Enghardt W, et al. Radiotherapy for chordomas and low-grade chondrosarcomas of the skull base with carbon ions. Int J Radiat Oncol Biol Phys 2002;53:36-42.
78. Berson AM, Castro JR, Petti P, Phillips TL, Gauger GE, Gutin P, et al. Charged particle irradiation of chordoma and chondrosarcoma of the base of skull and cervical spine: the Lawrence Berkeley Laboratory experience. Int J Radiat Oncol Biol Phys 1988;15:559-65.
79. Loeffler JS, Larsson DA, Shrieve DC. Radiosurgery for the treatment of intracranial lesions. In: De Vita V HS, Rosenberg A, editors. Important advances in oncology. Philadelphia: Lippincott; 1995. p. 141-56.
80. McCord MW, Buatti JM, Fennell EM, Mendenhall WM, Marcus RB, Jr, Rhoton AL, et al. Radiotherapy for pituitary adenoma: long-term outcome and sequelae. Int J Radiat Oncol Biol Phys 1997;39:437-44.
81. Grigsby PW, Stokes S, Marks JE, Simpson JR. Prognostic factors and results of radiotherapy alone in the management of pituitary adenomas. Int J Radiat Oncol Biol Phys 1988;15:1103-10.
82. Lillehei KO, Kirschman DL, Kleinschmidt-DeMasters BK, Ridgway EC. Reassessment of the role of radiation therapy in the treatment of endocrine-inactive pituitary macroadenomas. Neurosurgery 1998;43:432-8; discussion 438-9.
83. Landolt AM, Lomax N. Gamma knife radiosurgery for prolactinomas. J Neurosurg 2000;93(Suppl 3):14-8.
84. Kjellberg RN, Shintani A, Frantz AG, Kliman B. Proton-beam therapy in acromegaly. N Engl J Med 1968;278:689-95.
85. Minakova Y, Kerpatorskaya LY, Lyass FM. Proton beam therapy for pituitary adenomas. Med Radial (Moscow) 1983;28:7-13.
86. Levy RP, Fabricant JL, Lyman JT. Clinical results of sterotactic heavy-charged particle radiosurgery of the pituitary gland. In: Steiner et al, editor. Radiosurgery: baseline and trends. New York: Raven Press; 1992.
87. Egger E, Zografos L, Schalenbourg A, Beati D, Bohringer T, Chamot L, et al. Eye retention after proton beam radiotherapy for uveal melanoma. Int J Radiat Oncol Biol Phys 2003;55:867-80.
88. Egger E, Zografos L, Munkel G. Proton beam irradiation of Choroidal melanoma: Technique and Results. In: Brady LW, Heilmann H-P, Molls M, editors. Radiation therapy of Intraocular and Orbital Tumors, 2nd ed. Berlin: Springer Verlag; 2002. p. 67-80.
89. Goitein M, Miller T. Planning proton therapy of the eye. Med Phys 1983;10:275-83.
90. Gragoudas ES, Lane AM, Munzenrider J, Egan KM, Li W. Long-term risk of local failure after proton therapy for choroidal/ciliary body melanoma. Trans Am Ophthalmol Soc 2002;100:43-8; discussion 48-9.
91. Munzenrider JE, Gragoudas ES, Seddon JM, Sisterson J, McNulty P, Birnbaum S, et al. Conservative treatment of uveal melanoma: probability of eye retention after proton treatment. Int J Radiat Oncol Biol Phys 1988;15:553-8.
92. Naeser P, Blomquist E, Montelius A, Thoumas KA. Proton irradiation of malignant uveal melanoma. A five year follow-up of patients treated in Uppsala, Sweden. Ups J Med Sci 1998;103:203-11.
93. Nag S, Quivey JM, Earle JD, Followill D, Fontanesi J, Finger PT. The American Brachytherapy Society recommendations for brachytherapy of uveal melanomas. Int J Radiat Oncol Biol Phys 2003;56:544-55.